Your browser doesn't support javascript.
Discriminating promiscuous from target-specific autoantibodies in COVID-19.
Lebedin, Mikhail; García, Clara Vázquez; Spatt, Lisa; Ratswohl, Christoph; Thibeault, Charlotte; Ostendorf, Lennard; Alexander, Tobias; Paul, Friedemann; Sander, Leif Erik; Kurth, Florian; de la Rosa, Kathrin.
  • Lebedin M; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • García CV; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Spatt L; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Ratswohl C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Thibeault C; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Ostendorf L; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Alexander T; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Paul F; Department of Nephrology and Medical Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Sander LE; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kurth F; Deutsches Rheumaforschungszentrum (DRFZ Berlin) - a Leibniz Institute, Berlin, Germany.
  • de la Rosa K; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Eur J Immunol ; 53(5): e2250210, 2023 05.
Article in English | MEDLINE | ID: covidwho-2268156
ABSTRACT
Diverse autoantibodies were suggested to contribute to severe outcomes of COVID-19, but their functional implications are largely unclear. ACE2, the SARS-CoV-2 receptor and a key regulator of blood pressure, was described to be one of many targets of autoantibodies in COVID-19. ACE2 in its soluble form (sACE2) is highly elevated in the blood of critically ill patients, raising the question of whether sACE2spike complexes induce ACE2 reactivity. Screening 247 COVID-19 patients, we observed elevated sACE2 and anti-ACE2 IgG that were poorly correlated. Interestingly, levels of IgGs recognizing ACE2, IFNα2, and CD26 strongly correlated in severe COVID-19, with 15% of sera showing polyreactivity versus 4.1% exhibiting target-directed autoimmunity. Promiscuous autoantibodies failed to impair the activity of ACE2 and IFNα2, while only specific anti-IFNα2 IgG compromised cytokine function. Our study suggests that the detection of autoantibodies in COVID-19 is often attributed to a promiscuous reactivity, potentially misinterpreted as target-specific autoimmunity with functional impact.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Diagnostic study Limits: Humans Language: English Journal: Eur J Immunol Year: 2023 Document Type: Article Affiliation country: Eji.202250210

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Diagnostic study Limits: Humans Language: English Journal: Eur J Immunol Year: 2023 Document Type: Article Affiliation country: Eji.202250210